{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T18:24:48Z","timestamp":1789583088799,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T00:00:00Z","timestamp":1574121600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T00:00:00Z","timestamp":1574121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To assess the efficacy of Nimotuzumab in combination with first-line chemoradiotherapy treatment in Chinese patients with primary III-IVb stage nasopharyngeal carcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with primary locoregionally advanced nasopharyngeal carcinoma who were treated with intensity-modulated radiotherapy (IMRT) and concurrent cisplatin-based chemotherapy between January 2008 and December 2013 at a single institution were retrospectively reviewed. Group A received at least 6 doses of Nimotuzumab, while Group B did not receive Nimotuzumab. A propensity score matching method was used to match patients from each group in a 1:3 ratio.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 730 eligible patients were propensity matched, with 184 patients in Group A and 546 patients in Group B. Significant differences were not observed in the patient and tumor characteristics between Group A and Group B. At a median follow-up of 74.78\u2009months (range 3.53\u2013117.83\u2009months), locoregional recurrence, distant failure and death were observed in 10.68, 11.10 and 16.03% of all patients, respectively. The estimated 5-year locoregional relapse\u2013free survival, distant metastasis\u2013free survival, progression-free survival and overall survival in the Group A versus Group B were 85.34% versus 89.79% (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u20090.156), 93.09% versus 85.61% (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u20090.012), 79.96% versus 77.99% (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u20090.117) and 88.91% versus 78.30% (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u20090.006), respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This nimotuzumab-containing regimen resulted in improved long-term survival of III-IVb stage NPC patients and warrants further prospective evaluation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-019-6156-5","type":"journal-article","created":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T02:01:44Z","timestamp":1574128904000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["The long-term survival of patients with III-IVb stage nasopharyngeal carcinoma treated with IMRT with or without Nimotuzumab: a propensity score-matched analysis"],"prefix":"10.1186","volume":"19","author":[{"given":"Wang","family":"Zhi-Qiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Ji-Bin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You","family":"Rui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"You-Ping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun","family":"Rui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Guang-Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Ming-Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0998-8695","authenticated-orcid":false,"given":"Hua","family":"Yi-Jun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,19]]},"reference":[{"issue":"8","key":"6156_CR1","first-page":"381","volume":"33","author":"KR Wei","year":"2014","unstructured":"Wei KR, Zheng RS, Zhang SW, Liang ZH, Ou ZX, Chen WQ. Nasopharyngeal carcinoma incidence and mortality in China in 2010. Chin J Cancer. 2014;33(8):381\u20137.","journal-title":"Chin J Cancer."},{"issue":"9476","key":"6156_CR2","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1016\/S0140-6736(05)66698-6","volume":"365","author":"WI Wei","year":"2005","unstructured":"Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet. 2005;365(9476):2041\u201354.","journal-title":"Lancet."},{"issue":"8","key":"6156_CR3","first-page":"350","volume":"34","author":"LF Zhang","year":"2015","unstructured":"Zhang LF, Li YH, Xie SH, Ling W, Chen SH, Liu Q, et al. Incidence trend of nasopharyngeal carcinoma from 1987 to 2011 in Sihui County, Guangdong Province, South China: an age-period-cohort analysis. Chin J Cancer. 2015;34(8):350\u20137.","journal-title":"Chin J Cancer."},{"issue":"5","key":"6156_CR4","doi-asserted-by":"publisher","first-page":"517","DOI":"10.5732\/cjc.009.10329","volume":"29","author":"JT Wee","year":"2010","unstructured":"Wee JT, Ha TC, Loong SL, Qian CN. Is nasopharyngeal cancer really a \"Cantonese cancer\"? Chin J Cancer. 2010;29(5):517\u201326.","journal-title":"Chin J Cancer."},{"issue":"22","key":"6156_CR5","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.1200\/JCO.2008.19.9109","volume":"27","author":"N Lee","year":"2009","unstructured":"Lee N, Harris J, Garden AS, Straube W, Glisson B, Xia P, et al. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J Clin Oncol. 2009;27(22):3684\u201390.","journal-title":"J Clin Oncol"},{"issue":"10","key":"6156_CR6","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1002\/hed.10307","volume":"25","author":"BB Ma","year":"2003","unstructured":"Ma BB, Poon TC, To KF, Zee B, Mo FK, Chan CM, et al. Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma--a prospective study. Head Neck. 2003;25(10):864\u201372.","journal-title":"Head Neck"},{"issue":"10","key":"6156_CR7","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1097\/CAD.0b013e3283330590","volume":"20","author":"H Modjtahedi","year":"2009","unstructured":"Modjtahedi H, Essapen S. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anti-Cancer Drugs. 2009;20(10):851\u20135.","journal-title":"Anti-Cancer Drugs"},{"key":"6156_CR8","first-page":"457","volume":"7","author":"ZC Zhang","year":"2014","unstructured":"Zhang ZC, Fu S, Wang F, Wang HY, Zeng YX, Shao JY. Oncogene mutational profile in nasopharyngeal carcinoma. Onco Targets Ther. 2014;7:457\u201367.","journal-title":"Onco Targets Ther"},{"issue":"1","key":"6156_CR9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3892\/ol.2014.2631","volume":"9","author":"P Zhang","year":"2015","unstructured":"Zhang P, Wu SK, Wang Y, Fan ZX, Li CR, Feng M, et al. p53, MDM2, eIF4E and EGFR expression in nasopharyngeal carcinoma and their correlation with clinicopathological characteristics and prognosis: a retrospective study. Oncol Lett. 2015;9(1):113\u20138.","journal-title":"Oncol Lett"},{"issue":"8","key":"6156_CR10","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1080\/14737140.2016.1202116","volume":"16","author":"NP Campbell","year":"2016","unstructured":"Campbell NP, Hensing TA, Bhayani MK, Shaikh AY, Brockstein BE. Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck. Expert Rev Anticancer Ther. 2016;16(8):847\u201358.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"14","key":"6156_CR11","doi-asserted-by":"publisher","first-page":"5851","DOI":"10.1158\/0008-5472.CAN-08-4518","volume":"69","author":"A Talavera","year":"2009","unstructured":"Talavera A, Friemann R, Gomez-Puerta S, Martinez-Fleites C, Garrido G, Rabasa A, et al. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res. 2009;69(14):5851\u20139.","journal-title":"Cancer Res"},{"issue":"8","key":"6156_CR12","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1111\/1759-7714.12789","volume":"9","author":"X Si","year":"2018","unstructured":"Si X, Wu S, Wang H, Zhang X, Wang M, Zeng X, et al. Nimotuzumab combined with chemotherapy as first-line treatment for advanced lung squamous cell carcinoma. Thorac Cancer. 2018;9(8):1056\u201361.","journal-title":"Thorac Cancer"},{"issue":"4","key":"6156_CR13","doi-asserted-by":"publisher","first-page":"373","DOI":"10.4161\/cbt.11.4.14097","volume":"11","author":"G Garrido","year":"2011","unstructured":"Garrido G, Tikhomirov IA, Rabasa A, Yang E, Gracia E, Iznaga N, et al. Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile. Cancer Biol Ther. 2011;11(4):373\u201382.","journal-title":"Cancer Biol Ther"},{"issue":"17","key":"6156_CR14","doi-asserted-by":"crossref","first-page":"24429","DOI":"10.18632\/oncotarget.8225","volume":"7","author":"ZG Liu","year":"2016","unstructured":"Liu ZG, Zhao Y, Tang J, Zhou YJ, Yang WJ, Qiu YF, et al. Nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a retrospective analysis. Oncotarget. 2016;7(17):24429\u201335.","journal-title":"Oncotarget."},{"issue":"8","key":"6156_CR15","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.7150\/thno.19710","volume":"7","author":"R You","year":"2017","unstructured":"You R, Hua YJ, Liu YP, Yang Q, Zhang YN, Li JB, et al. Concurrent Chemoradiotherapy with or without anti-EGFR-targeted treatment for stage II-IVb nasopharyngeal carcinoma: retrospective analysis with a large cohort and long follow-up. Theranostics. 2017;7(8):2314\u201324.","journal-title":"Theranostics."},{"issue":"5","key":"6156_CR16","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","volume":"31","author":"JD Cox","year":"1995","unstructured":"Cox JD, Stetz J, Pajak TF. Toxicity criteria of the radiation therapy oncology group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31(5):1341\u20136.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"6156_CR17","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.ijrobp.2009.11.024","volume":"79","author":"WT Ng","year":"2011","unstructured":"Ng WT, Lee MC, Hung WM, Choi CW, Lee KC, Chan OS, et al. Clinical outcomes and patterns of failure after intensity-modulated radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2011;79(2):420\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"18","key":"6156_CR18","doi-asserted-by":"publisher","first-page":"3422","DOI":"10.1016\/j.ejca.2012.06.016","volume":"48","author":"YJ Hua","year":"2012","unstructured":"Hua YJ, Han F, Lu LX, Mai HQ, Guo X, Hong MH, et al. Long-term treatment outcome of recurrent nasopharyngeal carcinoma treated with salvage intensity modulated radiotherapy. Eur J Cancer. 2012;48(18):3422\u20138.","journal-title":"Eur J Cancer"},{"key":"6156_CR19","first-page":"814948","volume":"2014","author":"W Wang","year":"2014","unstructured":"Wang W, Feng M, Fan Z, Li J, Lang J. Clinical outcomes and prognostic factors of 695 nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy. Biomed Res Int. 2014;2014:814948.","journal-title":"Biomed Res Int"},{"key":"6156_CR20","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.oraloncology.2015.11.015","volume":"53","author":"J Setton","year":"2016","unstructured":"Setton J, Han J, Kannarunimit D, Wuu YR, Rosenberg SA, DeSelm C, et al. Long-term patterns of relapse and survival following definitive intensity-modulated radiotherapy for non-endemic nasopharyngeal carcinoma. Oral Oncol. 2016;53:67\u201373.","journal-title":"Oral Oncol"},{"issue":"17","key":"6156_CR21","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1016\/j.ejca.2015.08.006","volume":"51","author":"MX Zhang","year":"2015","unstructured":"Zhang MX, Li J, Shen GP, Zou X, Xu JJ, Jiang R, et al. Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: a 10-year experience with a large cohort and long follow-up. Eur J Cancer. 2015;51(17):2587\u201395.","journal-title":"Eur J Cancer"},{"issue":"4","key":"6156_CR22","first-page":"177","volume":"34","author":"JW Zhang","year":"2015","unstructured":"Zhang JW, Qin T, Hong SD, Zhang J, Fang WF, Zhao YY, et al. Multiple oncogenic mutations related to targeted therapy in nasopharyngeal carcinoma. Chin J Cancer. 2015;34(4):177\u201383.","journal-title":"Chin J Cancer"},{"issue":"1","key":"6156_CR23","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1186\/s12885-016-2974-x","volume":"16","author":"HM Li","year":"2016","unstructured":"Li HM, Li P, Qian YJ, Wu X, Xie L, Wang F, et al. A retrospective paired study: efficacy and toxicity of nimotuzumab versus cisplatin concurrent with radiotherapy in nasopharyngeal carcinoma. BMC Cancer. 2016;16(1):946.","journal-title":"BMC Cancer"},{"issue":"6","key":"6156_CR24","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/ijc.10647","volume":"101","author":"T Crombet-Ramos","year":"2002","unstructured":"Crombet-Ramos T, Rak J, Perez R, Viloria-Petit A. Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: a humanized anti-EGFR antibody. Int J Cancer. 2002;101(6):567\u201375.","journal-title":"Int J Cancer"},{"issue":"9","key":"6156_CR25","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1200\/JCO.2004.03.089","volume":"22","author":"T Crombet","year":"2004","unstructured":"Crombet T, Osorio M, Cruz T, Roca C, del Castillo R, Mon R, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol. 2004;22(9):1646\u201354.","journal-title":"J Clin Oncol"},{"issue":"1","key":"6156_CR26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.4161\/mabs.1.1.7509","volume":"1","author":"MS Ramakrishnan","year":"2009","unstructured":"Ramakrishnan MS, Eswaraiah A, Crombet T, Piedra P, Saurez G, Iyer H, et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs. 2009;1(1):41\u20138.","journal-title":"MAbs."},{"issue":"1","key":"6156_CR27","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s40880-016-0167-2","volume":"35","author":"YP Mao","year":"2016","unstructured":"Mao YP, Tang LL, Chen L, Sun Y, Qi ZY, Zhou GQ, et al. Prognostic factors and failure patterns in non-metastatic nasopharyngeal carcinoma after intensity-modulated radiotherapy. Chin J Cancer. 2016;35(1):103.","journal-title":"Chin J Cancer."},{"issue":"7","key":"6156_CR28","first-page":"699","volume":"61","author":"Y Qu","year":"2015","unstructured":"Qu Y, Chen Y, Yu H, Zhao Y, Chen G, Bai L, et al. Survival and prognostic analysis of primary nasopharyngeal carcinoma in North China. Clin Lab. 2015;61(7):699\u2013708.","journal-title":"Clin Lab"},{"key":"6156_CR29","doi-asserted-by":"crossref","unstructured":"Yao JJ, Zhang LL, Gao TS, Peng YL, Lawrence WR, Zhang WJ, et al. Comparing treatment outcomes of concurrent chemoradiotherapy with or without nimotuzumab in patients with locoregionally advanced nasopharyngeal carcinoma. Cancer Biol Ther. 2018:1\u20136.","DOI":"10.1080\/15384047.2018.1491501"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6156-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-6156-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6156-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T21:37:21Z","timestamp":1665005841000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-6156-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,19]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["6156"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-6156-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.10899\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.10899\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.10899\/v2","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,19]]},"assertion":[{"value":"10 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study complied with the standards of the Declaration of Helsinki and current ethical guidelines. It was approved by the Sun Yat-sen University Cancer Center research ethics committee. All patients provided written informed consent for the collection and publication of their medical information at the first visit to our center, which was filed in their medical records.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1122"}}